Syed Altaf Rabiya Riffath, Mohan Agilandeswari, Palani Naveen, Mendonce Keren Celestina, Monisha P, Rajadesingu Suriyaprakash
Department of Physics and Nanotechnology, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India; Centre for Research in Environment, Sustainability Advocacy and Climate CHange (REACH), Directorate of Research, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India.
Department of BioChemistry, Faculty of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India; Centre for Research in Environment, Sustainability Advocacy and Climate CHange (REACH), Directorate of Research, SRM Institute of Science and Technology, Kattankulathur 603203, Chengalpattu District, Tamil Nadu, India.
Int J Pharm. 2025 Jan 25;669:125053. doi: 10.1016/j.ijpharm.2024.125053. Epub 2024 Dec 10.
Developing nanocarriers that can carry medications directly to tumors is an exciting development in cancer nanomedicine. The efficacy of this intriguing therapeutic approach is, however, compromised by intricate and immunosuppressive circumstances that arise concurrently with the onset of cancer. The artificial antigen presenting cell (aAPC), a micro or nanoparticle based device that mimics an antigen presenting cell by providing crucial signal proteins to T lymphocytes to activate them against cancer, is one cutting-edge method for cancer immunotherapy. This review delves into the critical design considerations for aAPCs, particularly focusing on particle size, shape, and the non-uniform distribution of T cell activating proteins on their surfaces. Adequate surface contact between T cells and aAPCs is essential for activation, prompting engineers to develop nano-aAPCs with microscale contact areas through techniques such as shape modification and nanoparticle clustering. Additionally, we explore recommendations for future advancements in this field.
开发能够将药物直接输送到肿瘤的纳米载体是癌症纳米医学领域一项令人兴奋的进展。然而，这种引人入胜的治疗方法的疗效受到癌症发生时同时出现的复杂和免疫抑制环境的影响。人工抗原呈递细胞（aAPC）是一种基于微米或纳米颗粒的装置，通过向T淋巴细胞提供关键信号蛋白来模拟抗原呈递细胞，从而激活它们对抗癌症，这是癌症免疫治疗的一种前沿方法。本综述深入探讨了aAPC的关键设计考虑因素，特别关注颗粒大小、形状以及T细胞激活蛋白在其表面的不均匀分布。T细胞与aAPC之间充分的表面接触对于激活至关重要，这促使工程师通过形状修饰和纳米颗粒聚集等技术开发具有微米级接触面积的纳米aAPC。此外，我们还探讨了该领域未来进展的建议。
